Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Initiating oral fingolimod treatment in patients with multiple sclerosis.

Singer BA.

Ther Adv Neurol Disord. 2013 Jul;6(4):269-75. doi: 10.1177/1756285613491520.

2.

Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.

Singer B, Ross AP, Tobias K.

Int J Clin Pract. 2011 Aug;65(8):887-95. doi: 10.1111/j.1742-1241.2011.02721.x. Epub 2011 Jun 16. Review.

PMID:
21679286
3.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

5.

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Scott LJ.

CNS Drugs. 2011 Aug;25(8):673-98. doi: 10.2165/11207350-000000000-00000. Review.

PMID:
21790210
6.

Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.

Agashivala N, Kim E.

Clin Ther. 2012 Jul;34(7):1583-90. doi: 10.1016/j.clinthera.2012.06.012. Epub 2012 Jun 28.

PMID:
22749258
7.

Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.

Yeh EA, Weinstock-Guttman B.

Adv Ther. 2011 Apr;28(4):270-8. doi: 10.1007/s12325-011-0004-6. Epub 2011 Mar 7. Review.

PMID:
21394595
8.

Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.

Ward MD, Jones DE, Goldman MD.

Expert Opin Drug Saf. 2014 Jul;13(7):989-98. doi: 10.1517/14740338.2014.920820. Review.

PMID:
24935480
9.

Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.

Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N.

Adv Ther. 2014 Oct;31(10):1072-81. doi: 10.1007/s12325-014-0154-4. Epub 2014 Sep 23.

PMID:
25245812
10.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

11.

Clinical pharmacokinetics of fingolimod.

David OJ, Kovarik JM, Schmouder RL.

Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000. Review.

PMID:
22149256
12.

Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.

Tanasescu R, Constantinescu CS.

Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):621-30. doi: 10.1517/17425255.2014.894019. Epub 2014 Mar 1. Review.

PMID:
24579791
13.

Fingolimod and cardiac risk: latest findings and clinical implications.

Vargas WS, Perumal JS.

Ther Adv Drug Saf. 2013 Jun;4(3):119-24. doi: 10.1177/2042098613481023.

14.

Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.

Fazekas F, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Panayiotou P, Jazbec SS, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Havrdová E.

Wien Med Wochenschr. 2012 Aug;162(15-16):354-66. Epub 2012 Aug 16. Review. Erratum in: Wien Med Wochenschr. 2013 May;163(9-10):251. Multiple author names added.

15.

Fingolimod for the treatment of relapsing multiple sclerosis.

Singer BA.

Expert Rev Neurother. 2013 Jun;13(6):589-602. doi: 10.1586/ern.13.52. Review.

PMID:
23738997
16.

[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].

Széplaki G, Merkely B.

Ideggyogy Sz. 2012 Nov 30;65(11-12):369-76. Review. Hungarian.

PMID:
23289171
17.

Fingolimod for the treatment of relapsing multiple sclerosis.

Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.

Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16. Review.

PMID:
21158700
18.

Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.

Ordoñez-Boschetti L, Rey R, Cruz A, Sinha A, Reynolds T, Frider N, Alvarenga R.

Adv Ther. 2015 Jul;32(7):626-35. doi: 10.1007/s12325-015-0224-2. Epub 2015 Jul 14. Erratum in: Adv Ther. 2015 Jul;32(7):636.

19.

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.

Ayzenberg I, Hoepner R, Kleiter I.

Ther Clin Risk Manag. 2016 Feb 19;12:261-72. doi: 10.2147/TCRM.S65558. eCollection 2016. Review.

20.

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).

Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA; TRANSFORMS Study Group.

Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12.

PMID:
25876473

Supplemental Content

Support Center